Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human CPT1A Anticorps:
anti-Mouse (Murine) CPT1A Anticorps:
anti-Rat (Rattus) CPT1A Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal CPT1A Primary Antibody pour IHC (p), IHC - ABIN251677
Rayner, Esau, Hussain, McDaniel, Marshall, van Gils, Ray, Sheedy, Goedeke, Liu, Khatsenko, Kaimal, Lees, Fernandez-Hernando, Fisher, Temel, Moore: Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. dans Nature 2011
Show all 5 Pubmed References
Cow (Bovine) Polyclonal CPT1A Primary Antibody pour IHC, WB - ABIN2782010
Roomets, Kivelä, Tyni: Carnitine palmitoyltransferase I and Acyl-CoA dehydrogenase 9 in retina: insights of retinopathy in mitochondrial trifunctional protein defects. dans Investigative ophthalmology & visual science 2008
Show all 4 Pubmed References
Human Polyclonal CPT1A Primary Antibody pour IF (p), IHC (p) - ABIN677018
Fan, Wang, Ge, Wang, Li, Kong: Betaine supplementation protects against high-fructose-induced renal injury in rats. dans The Journal of nutritional biochemistry 2014
Show all 2 Pubmed References
Mouse (Murine) Polyclonal CPT1A Primary Antibody pour ELISA - ABIN451728
Mazzarelli, Pucci, Bonanno, Sesti, Calvani, Spagnoli: Carnitine palmitoyltransferase I in human carcinomas: a novel role in histone deacetylation? dans Cancer biology & therapy 2008
We provide evidence that the downregulation of hsa (Montrer CD24 Anticorps)-miR (Montrer MLXIP Anticorps)-124-3p, hsa (Montrer CD24 Anticorps)-miR (Montrer MLXIP Anticorps)-129-5p and hsa (Montrer CD24 Anticorps)-miR (Montrer MLXIP Anticorps)-378 induced an increase in both expression and activity of CPT1A, CACT (Montrer SLC25A20 Anticorps) and CrAT (Montrer CRAT Anticorps) in malignant prostate cells.
The recent findings and the current understanding of fatty acid oxidation and CPT1A in cancer have been summarized thus providing theoretical basis for this enzyme as an emerging potential molecular target in cancer therapeutic intervention. (Review)
Methylation of a CpG site in CPT1A is associated with circulating adiponectin levels, likely in an obesity-dependent manner, in three population-based adult cohorts of European descent.
Furthermore, given the already low abundance of Cpt1b (Montrer CPT1B Anticorps) in white adipose tissue, it is unlikely that decreases in its expression can quantitatively decrease whole body energy expenditure enough to contribute to an obese phenotype.
Data show that in the absence of indoleamine 2,3-dioxygenase (IDO (Montrer IDO1 Anticorps)) inhibition, fatty acid oxidation increased along with increased activity of carnitine palmitoyltransferase I (CPT1).
our results proved CPT1A as a potential prognosticator and therapeutic target for AML (Montrer RUNX1 Anticorps).
High CPT1A expression is associated with ovarian cancer.
Methylation at 2 CpG sites in CPT1A on chromosome 11 was significantly associated with MetS (Montrer ETV3 Anticorps). Significant associations were replicated in both European and African ancestry participants.
CPT1 is active on the outer surface of mitochondria and serves as a regulatory site for fatty acid oxidation due to its sensitivity for malonyl-CoA. CPT1a is the hepatic isoform.
the structure of the regulatory domain of CPT1C (Montrer CPT1C Anticorps) was determined (residues Met1 (Montrer GZMM Anticorps)-Phe50) by NMR spectroscopy.
acetate is the primary product of hepatic mitochondrial beta-oxidation in Sus scrofa and that regulation during early development is mediated primarily via kinetic modulation of CPT I (Montrer CPT1B Anticorps)
This study evaluated the effects of nonesterified fatty acids and glucose on carnitine palmitoyltransferase-I (CPT-I) mRNA expression in cultured bovine hepatocytes using real-time reverse transcription polymerase chain reaction and ELISA methods.
It was conclude that suppression of CPT (Montrer DHDDS Anticorps) activity by positive energy balance appears to be specific for the liver in mid-lactating dairy cows.
beneficial effects of muscle CPT1mt expression suggest that a direct modulation of the malonyl-CoA/CPT1 partnership in skeletal muscle could represent a potential strategy to prevent obesity-induced insulin (Montrer INS Anticorps) resistance
The data suggest that AMPK (Montrer PRKAA1 Anticorps) is not required for the regulation of the intermediate filament interaction with CPT-I during exercise.
these results demonstrated that L-carnitine ameliorated liver inflammation and serum pro-inflammatory markers in cancer cachexia through regulating CPT I-dependent PPARg (Montrer PPARG Anticorps) signaling
-Carnitine exerts its ameliorative effects in cancer cachexia in association with the PPAR-gamma (Montrer PPARG Anticorps) signaling pathway.
Data show that peroxisome-proliferator-activated receptor beta (Montrer PPARD Anticorps)/delta (PPARbeta (Montrer PPARD Anticorps)/delta) activation restored the lipid-induced endothelial dysfunction by up-regulation of carnitine palmitoyltransferase)-1 (CPT-1).
Our results indicated that exercise-induced CPT1b (Montrer CPT1B Anticorps) expression was at least in part mediated by HDAC5 (Montrer HDAC5 Anticorps)/MEF2A (Montrer MEF2A Anticorps) interaction.
an environment-dependent structural switch underlies the regulation of carnitine palmitoyltransferase 1A
miR (Montrer MLXIP Anticorps)-370 acting via miR (Montrer MLXIP Anticorps)-122 may have a causative role in the accumulation of hepatic triglycerides by modulating initially the expression of SREBP-1c (Montrer SREBF1 Anticorps), DGAT2 (Montrer DGAT2 Anticorps), and Cpt1alpha.
Results show that CREB (Montrer CREB1 Anticorps) and HNF4alpha (Montrer HNF4A Anticorps) bind the CPT (Montrer DHDDS Anticorps) promoter, that PGC-1 (Montrer PPARGC1A Anticorps) is involved in liver carnitine palmitoyltransferase I (CPT (Montrer DHDDS Anticorps)) gene activation by cylic AMP (Montrer TMPRSS5 Anticorps), and that PGC-1 (Montrer PPARGC1A Anticorps) acts to coordinate the process of metabolic adaptation in the liver.
The mitochondrial oxidation of long-chain fatty acids is initiated by the sequential action of carnitine palmitoyltransferase I (which is located in the outer membrane and is detergent-labile) and carnitine palmitoyltransferase II (which is located in the inner membrane and is detergent-stable), together with a carnitine-acylcarnitine translocase. CPT I is the key enzyme in the carnitine-dependent transport across the mitochondrial inner membrane and its deficiency results in a decreased rate of fatty acid beta-oxidation. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
carnitine palmitoyltransferase 1A (liver)
, carnitine O-palmitoyltransferase 1, liver isoform-like
, CPT I
, carnitine O-palmitoyltransferase 1, liver isoform
, carnitine O-palmitoyltransferase I, liver isoform
, carnitine palmitoyltransferase I, liver
, carnitine palmitoyl transferase I liver isoform
, liver type carnitine palmitoyltransferase I
, mitochondrial carnitine palmitoyltransferase 1A
, carnitine palmitoyltransferase 1A
, carnitine palmitoyltransferase I
, carnitine palmitoyl transferase I isoform
, L-CPT I
, carnitine palmitoyltransferase 1, liver
, Carnitine palmitoyltransferase 1 alpha, liver isoform